Liver Disease Associated with Inflammatory Bowel Disease
DOI:
https://doi.org/10.24871/251202471-75Keywords:
Gastroenterology, Hepatology, Inflammatory Bowel Disease, Autoimmune Liver DiseaseAbstract
Inflammatory Bowel Disease (IBD) is a chronic condition characterized by persistent inflammation of the gastrointestinal tract, comprising ulcerative colitis (UC) and Crohn’s disease (CD). While the current global incidence of IBD exceeds 0.3% in Western nations, Indonesia reports a comparatively lower prevalence however with projections indicate a potential rise in incidence from 2020 to 2050. Hepatobiliary manifestation is one of the most common extraintestinal manifestations of IBD. Some of the liver disease associated with IBD had similar background immune response, inflammatory reaction, similar risk factor, or due to the treatment of IBD. Primary sclerosing cholangitis (PSC) has close association with IBD and both affect the prognostic and disease progression of each other. Non-alcoholic fatty liver disease (NAFLD) shares common metabolic risk factors. Several drugs used as the treatment of IBD might cause hepatic injury especially due to the long treatment duration of IBD. Hepatitis B reactivation is another concerning event found after prolonged used of immunosuppressive drugs of IBD. Therefore, close monitoring of liver function test periodically is a mandatory test to screen liver disease in IBD patients.
Keyword: Inflammatory bowel disease, liver disease, autoimmune hepatitis, drug-induced liver injury
References
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-78.
Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1999-2013;2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):17-30.
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology. 2021;18(1):56-66.
Caviglia GP, Garrone A, Bertolino C, Vanni R, Bretto E, Poshnjari A, et al. Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy. J Clin Med. 2023;12(2).
Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. Journal of Clinical Medicine [Internet]. 2020; 9(5).
Teixeira FV, Hosne RS, Sobrado CW. Management of ulcerative colitis: a clinical update. Journal of Coloproctology (Rio de Janeiro). 2015;35:230-7.
Heller F, Fromm A, Gitter A, Mankertz J, Schulzke J. Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. Mucosal immunology. 2008;1:S58-S61.
Bogale K, Maheshwari P, Kang M, Gorrepati VS, Dalessio S, Walter V, et al. Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease. Scientific Reports. 2022;12(1):10577.
Yarur AJ, Czul F, Levy C. Hepatobiliary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(9):1655-67.
DeFilippis EM, Kumar S. Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease. Dig Dis Sci. 2015;60(10):2873-80.
Yaccob A, Mari A. Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease. Frontline Gastroenterol. 2019;10(3):309-15.
Patel P, Dalal S. Hepatic Manifestations of Inflammatory Bowel Disease. Clinical Liver Disease. 2021;17(4):292-6.
Kummen M, Schrumpf E, Boberg KM. Liver abnormalities in bowel diseases. Best Pract Res Clin Gastroenterol. 2013;27(4):531-42.
Chazouilleres O, Beuers U, Bergquist A, Karlsen TH, Levy C, Samyn M, et al. EASL Clinical Practice Guidelines on sclerosing cholangitis. Journal of Hepatology. 2022;77(3):761-806.
Nakazawa T, Naitoh I, Hayashi K, Sano H, Miyabe K, Shimizu S, et al. Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity? World J Gastroenterol. 2014;20(12):3245-54.
de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956-71.
Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features. Gut Liver. 2018;12(1):17-29.
Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN. Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. Am J Gastroenterol. 2016;111(5):705-11.
Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2016;22(8):1937-44.
Sartini A, Gitto S, Bianchini M, Verga MC, Di Girolamo M, Bertani A, et al. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death & Disease. 2018;9(2):87.
Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. Journal of Crohn's and Colitis. 2022;16(5):852-62.
Núñez FP, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol. 2022;14(2):319-37.
Shamberg L, Vaziri H. Hepatotoxicity of Inflammatory Bowel Disease Medications. J Clin Gastroenterol. 2018;52(8):674-84.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
Loftus EV, Jr., Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19(2):179-89.
Kopylov U, Ben-Horin S, Seidman E. Therapeutic drug monitoring in inflammatory bowel disease. Ann Gastroenterol. 2014;27(4):304-12.
Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19(42):7327-40.
Fournier MR, Klein J, Minuk GY, Bernstein CN. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010;105(7):1620-6.
Rossi RE, Parisi I, Despott EJ, Burroughs AK, O'Beirne J, Conte D, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol. 2014;20(46):17352-9.
Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558-64.e3.
Rocha HC, Vilela EG. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. Gastroenterol Hepatol. 2022;45(2):83-90.
Wang R, Leong RW. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol. 2014;20(27):8783-9.
Nannegari V, Roque S, Rubin DT, Quera R. A Review of Inflammatory Bowel Disease in the Setting of Liver Transplantation. Gastroenterol Hepatol (N Y). 2014;10(10):626-30.
Sørensen J, Nielsen OH, Andersson M, Ainsworth MA, Ytting H, Bélard E, et al. Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011. Liver Int. 2018;38(3):532-41.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
